Understand the source comparison
FSA HSA Peptides Use Health Savings — Comparison
Peptide prescribed for diagnosed chronic inflammatory condition (e.g., BPC-157 for Crohn's disease) LOMN with ICD-10 K51.90 + itemised receipt + prescription 85–90% with complete documentation 7–10 business days Missing LOMN, vague diagnosis, no failed-treatme
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Peptide prescribed for diagnosed chronic inflammatory condition (e.g., BPC-157 for Crohn's disease)
- LOMN with ICD-10 K51.90 + itemised receipt + prescription
- 85–90% with complete documentation
- 7–10 business days
- Missing LOMN, vague diagnosis, no failed-treatment documentation
- Strong reimbursement case when properly documented. Chronic inflammatory diagnoses meet IRS medical necessity standard
- GLP-1 peptide prescribed off-label for obesity (e.g., semaglutide, tirzepatide)
- LOMN with ICD-10 E66.01 + BMI documentation + itemised receipt + prescription
- 70–80% (varies by administrator)
- 10–14 business days
- Obesity not documented as morbid (BMI <40), missing weight-loss attempt history
- Approval contingent on BMI ≥35 with comorbidities or ≥40 alone. Document prior weight-loss attempts
- Growth hormone secretagogue for documented GH deficiency (e.g., MK 677, CJC-1295)
- LOMN with ICD-10 E23.0 + IGF-1 lab results <150 ng/mL + itemised receipt + prescription
- 75–85%
- IGF-1 levels not low enough, no endocrinologist referral, peptide not named in LOMN
- Requires lab documentation. Peptides alone without deficiency testing will be rejected
- Peptide purchased for general wellness or anti-aging without diagnosed deficiency
- None (not eligible)
- 0%. Automatic denial
- Immediate rejection
- Not prescribed for medical treatment, no ICD-10 diagnosis, purchased for enhancement
- Not reimbursable under IRS rules. FSA/HSA covers treatment, not optimisation
- Cognitive peptide prescribed for documented neurodegenerative condition (e.g., cerebrolysin, dihexa)
- LOMN with ICD-10 G30.9 or F03.90 + cognitive assessment scores + itemised receipt + prescription
- 60–75% (emerging therapy. Higher scrutiny)
- 14–21 business days
- Experimental therapy flag, insufficient cognitive decline documentation, no neurologist involvement
- Higher documentation burden. Benefit administrators scrutinise non-standard therapies more heavily